High Hopes for Sanofi’s Enjaymo as Japan’s First CAD Therapy: Osaka University Professor

Osaka University Professor Junichi Nishimura Sanofi’s Enjaymo (sutimlimab), which grabbed regulatory approval in June as Japan’s first cold agglutinin disease (CAD) drug, is highly promising as a first-line treatment, Osaka University Professor Junichi Nishimura said on August 3. Prof. Nishimura,...read more